Patients with Obstructive Sleep Apnea in Germany

Overview

Journal Sleep Breath

Publisher Springer

Date 2025 Feb 27

PMID 40014191

Authors

Yaroslav Winter

Geert Mayer

Heike Benes

Lothar Burghaus

Samantha Floam

Gregory S Parks

Ulf Kallweit

Affiliations

Soon will be listed here.

Abstract

Purpose: Solriamfetol is approved for use in the European Union to treat excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA). SURWEY characterized real-world evidence regarding physician initiation and titration strategies and patient experiences with solriamfetol. We report SURWEY data for patients with OSA and EDS in Germany (N = 83).

Methods: SURWEY was a retrospective chart review conducted among physicians in Germany. Eligible patients were age ≥ 18 years who reached a stable solriamfetol dose and completed ≥ 6 weeks of treatment. Patients were grouped by solriamfetol initiation strategy: changeover, add-on, new-to-therapy.

Results: Patients' mean (SD) age was 49 (14) years. New-to-therapy was the most common initiation strategy. Solriamfetol was initiated at 37.5 mg/day in most patients (n = 57, 69%) and titrated in 53 patients (64%); 30 (57%) completed titration within 2 weeks. In a post-hoc analysis, mean (SD) Epworth Sleepiness Scale (ESS) score was 16.0 (3.2) at baseline and decreased by 5.4 (3.6) at final follow-up (~ 16 weeks; p <.001). Improvement in patient- and physician-rated EDS was reported by ~ 90% of patients. Most patients (55%) reported effects of solriamfetol lasting ≥ 8 h; 91% of patients reported no change in nighttime sleep quality. The most frequent adverse events were headache (8%), decreased appetite (7%), and insomnia (6%).

Conclusion: Most patients in this study were new to therapy. Solriamfetol was typically initiated at 37.5 mg/day; titration was common. ESS scores improved with solriamfetol treatment, and most patients self-reported improvement in EDS symptoms. Common adverse events were consistent with those reported in previous clinical trials.

References

Gasa M, Tamisier R, Launois S, Sapene M, Martin F, Stach B . Residual sleepiness in sleep apnea patients treated by continuous positive airway pressure. J Sleep Res. 2013; 22(4):389-97. DOI: 10.1111/jsr.12039. View

Kallweit U, Pevernagie D, Lammers G . "Sleepiness" in obstructive sleep apnea: getting into deep water. Sleep Med. 2022; 92:64-66. DOI: 10.1016/j.sleep.2022.02.015. View

Baladi M, Forster M, Gatch M, Mailman R, Hyman D, Carter L . Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor. J Pharmacol Exp Ther. 2018; 366(2):367-376. DOI: 10.1124/jpet.118.248120. View

Stepnowsky C, Sarmiento K, Bujanover S, Villa K, Li V, Flores N . Comorbidities, Health-Related Quality of Life, and Work Productivity Among People With Obstructive Sleep Apnea With Excessive Sleepiness: Findings From the 2016 US National Health and Wellness Survey. J Clin Sleep Med. 2019; 15(2):235-243. PMC: 6374092. DOI: 10.5664/jcsm.7624. View

Singh H, Hyman D, Parks G, Chen A, Foley C, Baldys B . Solriamfetol Titration and AdministRaTion (START) in Patients with Obstructive Sleep Apnea: A Retrospective Chart Review and Hypothetical Patient Scenario. Adv Ther. 2022; 39(9):4359-4373. PMC: 9402730. DOI: 10.1007/s12325-022-02249-4. View

Garbarino S, Guglielmi O, Sanna A, Mancardi G, Magnavita N . Risk of Occupational Accidents in Workers with Obstructive Sleep Apnea: Systematic Review and Meta-analysis. Sleep. 2016; 39(6):1211-8. PMC: 4863208. DOI: 10.5665/sleep.5834. View

Pepin J, Viot-Blanc V, Escourrou P, Racineux J, Sapene M, Levy P . Prevalence of residual excessive sleepiness in CPAP-treated sleep apnoea patients: the French multicentre study. Eur Respir J. 2009; 33(5):1062-7. DOI: 10.1183/09031936.00016808. View

Patel S, Kon S, M Nolan C, Barker R, Simonds A, Morrell M . The Epworth Sleepiness Scale: Minimum Clinically Important Difference in Obstructive Sleep Apnea. Am J Respir Crit Care Med. 2017; 197(7):961-963. PMC: 6020404. DOI: 10.1164/rccm.201704-0672LE. View

Schweitzer P, Rosenberg R, Zammit G, Gotfried M, Chen D, Carter L . Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial. Am J Respir Crit Care Med. 2018; 199(11):1421-1431. PMC: 6835071. DOI: 10.1164/rccm.201806-1100OC. View

10.

Bonsignore M, Pepin J, Cibella F, Barbera C, Marrone O, Verbraecken J . Excessive Daytime Sleepiness in Obstructive Sleep Apnea Patients Treated With Continuous Positive Airway Pressure: Data From the European Sleep Apnea Database. Front Neurol. 2021; 12:690008. PMC: 8381644. DOI: 10.3389/fneur.2021.690008. View

11.

Malhotra A, Shapiro C, Pepin J, Hedner J, Ahmed M, Foldvary-Schaefer N . Long-term study of the safety and maintenance of efficacy of solriamfetol (JZP-110) in the treatment of excessive sleepiness in participants with narcolepsy or obstructive sleep apnea. Sleep. 2019; 43(2). PMC: 7315408. DOI: 10.1093/sleep/zsz220. View

12.

Zhou J, Camacho M, Tang X, Kushida C . A review of neurocognitive function and obstructive sleep apnea with or without daytime sleepiness. Sleep Med. 2016; 23:99-108. DOI: 10.1016/j.sleep.2016.02.008. View

13.

Lal C, Weaver T, Bae C, Strohl K . Excessive Daytime Sleepiness in Obstructive Sleep Apnea. Mechanisms and Clinical Management. Ann Am Thorac Soc. 2021; 18(5):757-768. PMC: 8086534. DOI: 10.1513/AnnalsATS.202006-696FR. View

14.

Winter Y, Mayer G, Kotterba S, Benes H, Burghaus L, Koch A . Solriamfetol real world experience study (SURWEY): Initiation, titration, safety, effectiveness, and experience during follow-up for patients with narcolepsy from Germany. Sleep Med. 2023; 103:138-143. DOI: 10.1016/j.sleep.2023.01.022. View

15.

Johns M . A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991; 14(6):540-5. DOI: 10.1093/sleep/14.6.540. View

16.

Alnefeesi Y, Tamura J, Lui L, Jawad M, Ceban F, Ling S . Trace amine-associated receptor 1 (TAAR1): Potential application in mood disorders: A systematic review. Neurosci Biobehav Rev. 2021; 131:192-210. DOI: 10.1016/j.neubiorev.2021.09.020. View